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1. Introduction 
Maintenance of oxygen homeostasis is essential for the survival of all multicellular 
organisms. Specialized chemoreceptor cells can sense increased (hyperoxia) or decreased 
(hypoxia) oxygen levels and subsequently regulate cardiovascular and ventilatory rates. 
Additionally, all nucleated cells sense and respond to reduced O2 availability acutely, 
through the activation of proteins, and chronically, through the regulation of gene 
transcription. Decreased oxygen levels stimulate the oxygen delivery system and provide 
mechanisms to activate cell death or survival pathways, depending on the context of the 
hypoxia signal. Several responses are developed by cells and tissues faced with a hypoxic 
challenge, particularly in the heart: 1) increased ventilation and cardiac output, 2) a switch 
from aerobic to anaerobic metabolism, 3) promotion of improved vascularization via 
angiogenesis, and 4) enhanced O2 carrying capacity of the blood. Hypoxia occurs in 
physiological situations such as during embryonic development, as well as in pathological 
conditions such as ischemia, wound healing, and cancer.  
Angiogenesis is the process by which blood microvessels are formed from existing ones, 
which is required for development and occurs in pathological conditions. It is also 
important for reducing myocardial hypoxia due to coronary and ischemic heart disease. In 
myocardial infarction or chronic ischemic heart disease, angiogenesis responds to tissue 
hypoxia by new vessel formation, which diminishes myocardial ischemia. Nevertheless, 
physiological angiogenesis is usually insufficient to re-establish an adequate blood supply to 
the myocardium, which decreases its proper functioning. Therapeutic angiogenesis in the 
heart aims at increasing new vessel formation in ischemic myocardium and thus improving 
myocardial function by increasing blood flow (oxygen and nutrient supply). This may 
contribute to preventing heart failure and sudden cardiac death. However, hypoxia also 
stimulates several angiogenic inhibitors in the heart while pro-angiogenic factors are 
increased. This spontaneous balance reaction is one of the causes for the failure of 
angiogenic therapy for ischemia heart diseases. Unfortunately, the area of anti-angiogenesis 
in the heart has remained unclear. This chapter reviews the effects of both angiogenic and 
anti-angiogenic reactions in the heart dependent on the endothelial response to hypoxic 
/ischemic stimulation.  
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2. Hypoxia-regulated angiogenesis in the myocardium 
2.1 HIF1-α-mediated angiogenesis 
Hypoxia-stimulated myocardial angiogenesis has well been studied in past decades. 
When the myocardium is deprived of blood, a process of ischemia, infarction, and 
myocardial remodeling is initiated. Hypoxia-inducible factor 1 (HIF-1) is a transcriptional 
activator of vascular endothelial growth factor (VEGF) and is critical for initiating early 
cellular responses to hypoxia in specimens of human heart tissue (Lee et al., 2000). Upon 
initiation of the hypoxic signal, HIF1-ǂ translocates to the nucleus, dimerizes with HIF1-ǃ 
to form the HIF-1 complex and induces the expression of its transcriptional targets via 
binding to hypoxia-responsive elements (HREs) (Chilov et al., 1999). HREs are present in 
many angiogenic genes, such as VEGF, angiopoietin-2, VEGF receptors (Flt1 and KDR), 
and neuropilin-1 (Hickey and Simon, 2006; Simons, 2005). Hypoxia can up-regulate these 
angiogenic molecules by several mechanisms, including direct transcriptional activation 
by HIFs or indirect up-regulation by HIF-induced molecules. In addition, previous studies 
suggested that hypoxia/reoxygenation promotes myocardial angiogenesis via an NF 
kappa B-dependent mechanism in a rat model of chronic myocardial infarction (Sasaki et 
al., 2001). 
Additional transcription factors induced by hypoxia, such as Related Transcription 
Enhancer Factor-1 (RTEF-1) and early growth response 1 (EGR-1), can both target VEGF to 
enhance angiogenesis (Shie et al., 2004; Yan et al., 2000). Additional angiogenic growth 
factors such as IGF are also induced by hypoxia, but can signal through a HIF-1-
independent pathway (Slomiany and Rosenzweig, 2006).  
Moreover, hypoxia is associated with virtually all forms of vascular disorders, such as 
coronary and peripheral arterial diseases, including stroke, myocardial and limb ischemia; 
lung disorders; and diabetes (Fong, 2008). The post-ischemia neovascular response is largely 
driven by hypoxia-induced up-regulation and stabilization of VEGF, initiated in part by 
HIF1. In concert with enhanced expression of VEGF and its receptors, other growth factors 
and cellular receptors, including placental growth factor (PlGF), basic fibroblast growth 
factor (bFGF), IL-8 and ETS-1 are also differentially regulated in highly specific spatio-
temporal expression patterns, orchestrated to acutely minimize parenchymal damage and to 
optimize subsequent healing and recovery. Physiological stresses such as hypoxia are 
regulated by a complex balance of both stimulatory and inhibitory signals that promote or 
inhibit angiogenesis. Specifically, understanding the role and regulation of genes during 
angiogenesis is becoming increasingly important in elucidating the compensatory hypoxic 
response.  
2.2 Hypoxia upregulated microRNA-mediated angiogenesis 
Recent studies have revealed important roles for microRNAs (miRNAs, miRs) in regulating 
endothelial cell function, especially in angiogenesis. miRNAs are a class of conserved non-
coding small RNAs, with the ability to repress gene expression post-transcriptionally by 
targeting 3′-untranslated regions (3′UTRs) of mRNAs. Almost 700 miRNAs have been 
identified in humans, and the estimated number of miRNA genes is as high as 1000 in the 
human genome (Berezikov et al., 2005). Current evidence demonstrates that miRNAs are 
important regulators of angiogenesis as well as cardiovascular development and disease. 
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Pro-angiogenic miRs (angiomiRs) regulate angiogenesis, for example, by targeting negative 
regulators in angiogenic signaling pathways, while anti-angiomiRs inhibit angiogenesis by 
targeting positive regulators of angiogenesis. Let7-f, miR-27b, mir-130a, miR-424, miR-296, 
and miR-210 have been shown to be pro-angiomiRs (Fish et al., 2008; Ghosh et al., 2010; 
Urbich et al., 2008; Wurdinger et al., 2008). 
Let-7f and miR-27b exert pro-angiogenic effects as evidenced by the blockade of in vitro 
angiogenesis with 2′-O-methyl oligonucleotide inhibitors (Kuehbacher et al., 2008), while 
miR-210 is induced by hypoxia in endothelial cells and overexpression enhanced the 
formation of capillary-like structures. Additionally, overexpression of miR-210 enhanced 
VEGF-driven migration of normoxic endothelial cells, whereas inhibition of miR-210 
decreased tube formation and migration (Fasanaro et al., 2008). 
Endothelial overexpression of miR-424 increased proliferation and migration, as a result 
of autocrine stimulation by HIF-1ǂ–driven VEGF secretion. In addition to the in vitro 
changes in angiogenesis, miR-424 levels were significantly increased during vascular 
remodeling in vivo. Changes in miR-424 were observed in models of experimental 
myocardial infarction and PAD. Interestingly, the rodent homologue of miR-424, miR-322, 
was upregulated in peri-infarct cardiac tissues in rats following LAD ligation. Left 
ventricular tissues harvested away from the infarcted area also showed significantly 
higher levels of mu-miR-322. Ischemia seems to activate mu-miR-322 expression in the 
tissues surrounding the site of hypoxic stress as a survival mechanism to initiate collateral 
vessel growth (Ghosh et al. 2010). 
Neoangiogenesis is essential for cardiac repair following myocardial infaction, when 
collateral vessels form at the site of the infarct and can maintain blood flow to ischemic 
tissue. The endothelial-specific miR-126 plays a role in neoangiogenesis following 
myocardial infarction and in the maintenance of vascular integrity. miR-126 potentiates 
MAP kinase signaling downstream of VEGF and FGF via Spred-1, an intracellular 
inhibitor of the Ras/MAP kinase pathway. miR-126 over-expression relieves the 
repressive influence of Spred-1 on the signaling pathways activated by VEGF and FGF, 
inducing angiogenesis. Elevation of miR-126 expression in the ischemic myocardium 
could enhance cardiac repair (Wang et al., 2008). 
3. Therapeutic angiogenesis in the myocardium 
In coronary artery disease (CAD), progressive occlusion of arteries can lead to collateral 
vessel development to supply the ischemic tissue. In spite of this, angiogenesis via 
neovascularization is not always sufficient as evidenced by the large number of 
revascularization procedures performed annually. The lack of a sufficient angiogenic 
response in part may be related to both the decreased production of angiogenic factors as 
well as a natural negative feedback by the upregulation of anti-angiogenic molecules. 
Therapeutic angiogenesis involves improving blood flow to ischemic tissue by the induction 
of neovascularization by angiogenic agents administered as recombinant protein or by gene 
transfer. To circumvent insufficient collateral vessel development, administration of 
recombinant protein or the genes that encode these proteins have been used as techniques of 
angiogenic therapy in preclinical and clinical trials. Yet, results of these trials have only been 
slightly beneficial for patients.  
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4. Anti-angiogenic genes in response to hypoxia 
While hypoxia-induced VEGF initiates angiogenesis, it also up-regulates expression of 
molecules within the endothelium that act as negative feedback regulators to modulate 
excessive vascular sprouting and endothelial cell proliferation (Messmer-Blust et al., 2009). 
Additionally, a previous report by An et al. demonstrated that Response Gene to 
Complement (RGC)-32 is another important VEGF-inducible gene that serves as a negative 
regulator of hypoxia-induced angiogenesis. RGC-32 expression was significantly increased 
under hypoxic conditions. Hypoxic induction of RGC-32 was also mediated by HIF-1ǂ at 
both the transcriptional and posttranscriptional levels (An et al., 2009). While HIF-1-induced 
RGS5 was not VEGF-mediated (Jin et al., 2009), RGC-32 expression was significantly 
increased by VEGF but not by factors including TNF-ǂ, FGF2 and IL-1ǃ (An et al., 2009). 
Unlike genes such as COX-2 (Wu et al., 2003), RGC-32 did not follow the canonical VEGF-
induced angiogenic pathway. Overexpression of RGC-32 destabilized vascular structure 
formation in vitro by down-regulating FGF-2 and cyclin E, which caused negative feedback 
to VEGF activation. Additionally, when angiogenesis was examined in vivo in a mouse 
model, RGC-32 drastically inhibited VEGF-induced angiogenesis in matrigel, attenuated the 
recovery rate in hindlimb ischemia and reduced tumor size (An et al., 2009).  
VEGF also induces Delta-like ligand 4 (Dll4), a part of the Notch signaling pathway 
expressed in the vascular endothelium, yet has anti-angiogenic properties (Lobov et al., 
2007). Lobov, et al. demonstrated that Dll4 is an antagonistic regulator of angiogenesis by 
injecting a soluble version of Dll4 (Dll4-Fc) that blocks Dll4/Notch interactions into the 
vitreous membrane of oxygen-induced ischemic retinopathic (OIR) mice. Blocking Dll4 
significantly enhanced angiogenic sprouting while suppressing ectopic pathological neo-
vascularization in the retinal vasculature (Lobov et al., 2007). Therefore, Dll4 plays a role as a 
negative regulator of sprouting angiogenesis in response to the release of hypoxia-induced 
factors such as VEGF (Lobov et al., 2007).  
In addition to VEGF-induced anti-angiogenic genes, the hypoxia-induced VEGF itself is also 
subjected to negative regulation, such as by transcription factor E2F1 (Qin et al., 2006). 
Under hypoxic conditions, VEGF is induced by HIF-1; however, E2F1 down-regulates 
expression of VEGF by associating with p53 and specifically down-regulating VEGF 
expression but not other hypoxia-inducible genes. Studies of E2F1-/- mice under hypoxic 
conditions revealed enhanced angiogenesis dependent on de-regulated VEGF, which 
illustrates a novel negative regulation to VEGF. 
5. Anti-angiogenesis in myocardial ischemia 
Hypoxia, as a result of impaired blood flow, has a hazardous effect on organ structure and 
function, especially in the heart, i.e. myocardial ischemia. Acute coronary syndromes 
resulting from occlusion of one of the coronaries exposes the heart to ischemic conditions. 
Short periods of ischemia (~20 minutes) are reversible if followed by reperfusion. If 
coronary occlusion is prolonged, necrosis can propagate from subendocardium to 
subepicardium. Additionally, reperfusion beyond a few hours does not reduce myocardial 
infarct size.  
Functional recovery of the ischemic tissues and organs is dependent on re-establishing 
collateral networks that sufficiently supply hyper-oxygenated blood to specialized cell 
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populations. In response to ischemic insults, most tissues in the body have the capacity to 
compensate for low levels of oxygen by mechanisms of vasodilation, angiogenesis, 
arteriogenesis, vascular remodeling, and hematopoiesis (Boutin et al., 2008; Makino et al., 
2001). Coronary collateral vessels can increase blood flow to regions of the heart supplied by 
arteries with high-grade stenosis, thus protecting the myocardium from ischemia (Heinle et 
al., 1974). Collateral formation is highly variable between patients and only partially 
attributable to differences in the degree of the coronary artery occlusive disease. For 
therapeutic angiogenesis, it is essential to understand the molecular mechanisms of 
angiogenesis and arteriogenesis in relation to tissue hypoxia. 
Angiopoietin-2 (Ang2) is important in the inhibition of angiogenesis induced by hypoxia; 
previous reports determined that hypoxia enhances Ang2 expression both in vivo and in 
vitro (Oh et al., 1999). The angiopoietin ligands/Tie receptors belong to a class of 
ligand/receptor families that play a critical role in angiogenesis, cell migration, 
proliferation, and survival. Ang1 and Ang2 are both ligands with a similar binding affinity 
for the Tie2 receptor, which is a member of the receptor tyrosine kinases (RTKs) and is 
predominantly expressed by vascular endothelial cells (Maisonpierre et al., 1997). Ang1 
induces angiogenesis via autophosphorylation of Tie2, while Ang2 competitively inhibits 
this effect (Maisonpierre et al., 1997). Ang2 is an antagonist for the Ang1/Tie2 pathway, as 
supported by data from over-expressing Ang2 mice that showed a very similar phenotype 
to the Ang1 and Tie2 single knockouts (Yuan et al., 2009). Interestingly, Ang2 possesses both 
partial agonistic as well as antagonistic action on Tie2 in the endothelium; alone, Ang2 is a 
weak activator of Tie2, whereas in the presence of Ang1, Ang2 inhibits Tie2 signaling. When 
the endothelium is stimulated with Ang1 and Ang2, Ang2 dose-dependently inhibits Ang1-
induced Tie2 phosphorylation, Akt activation, as well as EC survival.  
Though in vitro experimental studies have shown that VEGF, Ang-2, and Tie-2 but not Ang-
1 expression is upregulated in ischemic myocardium, (Hashimoto et al., 1994; Matsunaga et 
al., 2003), clinical studies in patients with acute myocardial infarction have only shown 
increased peripheral blood VEGF (Kranz et al., 2000). However, a more recent study showed 
that in addition to increased VEGF and Tie-2 levels, Ang-2 levels were also increased. 
Additionally, patients with evidence of myocardial damage (ie, AMI) had the highest levels 
of Ang-2, VEGF, and Tie-2 compared with other groups (Lee et al., 2004).  
6. Feedback loops in angiogenic inhibition in response to hypoxia in the 
heart 
As a hypoxia-induced transcription factor, HIF-1 both stimulates and represses a multitude 
of genes important for adaptation to the low oxygen environment. Regulator of G protein 
Signaling 5 (RGS5) is a HIF-1-dependent, hypoxia-induced angiogenic inhibitor (Jin et al., 
2009) that functions as a negative regulator of G protein-mediated signaling (Adams et al., 
2000; Bell et al., 2001). Previous reports showed that hypoxia specifically increased RGS5 
expression in endothelial cells; RGS5 mRNA expression was induced by hypoxia while two 
other family members, RGS2 and RGS4, were not impacted (Jin et al., 2009). In addition to 
changes in oxygen levels, HIF-1ǂ played a key role in hypoxia-induced RGS5 expression by 
stimulating RGS5 promoter activity in endothelial cells. RGS5 slowed endothelial cell 
growth and significantly enhanced the apoptotic protein Bax, which led to increased 
apoptosis due to the change in the Bcl-2/Bax ratio (Jin et al., 2009; Yang and Korsmeyer, 
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1996). Furthermore, RGS5 inhibited VEGF-induced angiogenesis through the p38 MAPK-
dependent pathway in vitro and in vivo.  
Additionally, a more recent report demonstrated that insulin growth factor binding protein-
6 (IGFBP-6) was upregulated in vascular endothelial cells in response to prolonged hypoxia 
and can inhibit angiogenesis in vitro and in vivo (Zhang et al. 2011). Sequence analysis of the 
human IGFBP-6 promoter suggested that hypoxia induces the expression of IGFBP-6 in 
VECs, likely via a HIF-1-mediated mechanism, as there are 8 canonical HREs located in the 
promoter region of human IGFBP-6 gene. Interestingly, hypoxia has been shown to rapidly 
induce IGFBP-1 (Kajimura et al., 2005; Tazuke et al., 1998), whereas the up-regulation of the 
IGFBP-6 gene is not observed until 48 h of hypoxia, implying that IGFBP-6 induction by 
hypoxia may act as a negative feedback mechanism in hypoxia-induced angiogenesis.  
Furthermore, previous studies suggest that HIF1ǂ function is regulated by mitogen 
activated protein (MAP) kinases (Berra et al., 2000; Minet et al., 2000; Richard et al., 1999). 
Specifically, the closely related MAP kinase, BMK1/ERK5, is necessary for vasculature 
remodeling and maintenance. Embryos deficient for the BMK1 MAP kinase die between 
E10.5 and E11.5 due to angiogenic failure and cardiovascular defects. BMK1 deficiency leads 
to increased VEGF dysregulation, which impedes angiogenic remodeling and vascular 
stabilization. Additionally, BMK1 negatively regulates transcription from VEGF during 
hypoxia. Further research confirmed BMK negative regulation using a conditional BMK1 
knockout mouse, which revealed that vascular integrity was compromised and EC 
apoptosis was increased (Hayashi et al., 2004; Pi et al., 2004; Sohn et al., 2002). Upregulation 
of BMK1 negatively regulates HIF1ǂ and angiogenesis by increasing HIF1ǂ ubiquitination 
and degradation in endothelial cells (Pi et al., 2005).  
7. Hypoxia-induced apoptosis 
During angiogenesis, endothelial cells undergo proliferation, reorganization, and 
stabilization to establish a mature vascular network. Apoptosis occurring in endothelial cells 
causes an inhibitory effect on cell proliferation, which has a similar impact to that of anti-
angiogenic factors. Hypoxia promotes apoptosis in endothelial cells, as demonstrated by 
changes in p53 protein levels (Hammond and Giaccia, 2005; Stempien-Otero et al., 1999). 
Several studies suggest that HIF-1ǂ stabilizes p53 and contributes to hypoxia-induced p53-
dependent apoptosis (Xenaki et al., 2008). A recent report proposed that P300/CBP-
associated factor (PCAF), an HIF-1ǂ cofactor, regulates the balance between cell cycle arrest 
and apoptosis in hypoxia by modulating the activity and protein stability of both p53 and 
HIF-1ǂ (Xenaki et al., 2008). Previous reports demonstrated that p53 can also inhibit 
angiogenesis by the following mechanisms: elevating thrombospondin-1 levels, repressing 
both VEGF and FGF-2, and by inducing degradation of HIF-1 (Folkman, 2006).  
HIF-1ǂ mediates hypoxia-induced apoptosis through the up-regulation of genes as well as 
suppression of genes such as Bcl-2 (Carmeliet et al., 1998; Jin et al., 2009). One member of the 
Bcl-2 family, Bcl-2/E1B interacting protein (BNIP3) is up-regulated under hypoxic 
conditions (Chen et al., 1997; Kothari et al., 2003). Kothari and colleagues showed that 
blocking hypoxia-induced BNIP3 expression using siRNA or a mutant BNIP3 inhibits 
hypoxia-induced cell death. Additionally, hypoxia-mediated BNIP3 expression occurs by 
direct binding to an HRE in the human BNIP3 promoter, and mutation of this HRE site 
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eliminates the hypoxic responsiveness of the promoter. Furthermore, hypoxia-induced 
BNIP3 expression was detectable 24 h after initial up-regulation of HIF-1ǂ, indicating that 
BNIP3 expression occurs much later in the hypoxic response than genes such as VEGF 
(Kothari et al., 2003).  
 
Fig. 1. Schematic illustration of hypoxia/ischemia-induced factors that can balance the 
decision between pro- and anti-angiogenesis in endothelial cells (EC). It is classified by 
direct indirect induction through molecules such as HIF-1, VEGF and transcription factors. 
This delicate equilibrium can easily be influenced by diverse factors, including angiogenic 
cytokines, local remodeling of the ECM, growth factors, inflammation, and most 
importantly, exposure to hypoxia.  
While HIF-1 mainly targets pro-angiogenic genes, there are feedback molecules to 
counteract this up-regulation, such as endostatin, which down-regulates HIF-1ǂ (Abdollahi 
et al., 2004). Hypoxia-induced endostatin inhibits VEGF-induced angiogenesis by preventing 
proliferation and migration of endothelial cells (Abdollahi et al., 2004; Heljasvaara et al., 
2005; Morbidelli et al., 2003) and simultaneously up-regulates anti-angiogenic genes, 
including thrombospondin (TSP1), vasostatin, and kininogen (Abdollahi et al., 2004). 
Reduced oxygen supply in FVB mice exposed to a hypobaric hypoxia chamber showed 
enhanced MMP production leading to a subsequent increase of endostatin generation in the 
lung and aorta (Paddenberg et al., 2006). These results were confirmed by Suhr et. al, who 
reported a significant increase in the endostatin and MMP-9 plasma concentration following 
hypoxic conditions in human cyclists (Suhr et al., 2007). Further studies done on TSP-1 by 
Morgan-Rowe et. al. showed that it is induced in hypoxia-conditioned media and blocks 
miR-424 
www.intechopen.com
 
Coronary Artery Disease – New Insights and Novel Approaches 
 
110 
proliferation of HMEC-1 cells. Increased TSP-1 levels were found following 24 hours of 
hypoxia in the HMEC-1 media. Additionally, caspase 3 levels were increased followed by 
inhibition of proliferation and subsequent apoptosis, despite the elevation of VEGF 
(Morgan-Rowe et al., 2011).  
8. Equilibrium between hypoxia-induced angiogenesis and anti-
angiogenesis/apoptosis in the heart 
Hypoxia promotes pro- and anti-angiogenesis as well as apoptosis in endothelial cells. 
Apoptosis occurring in endothelial cells causes an inhibitory effect on cell proliferation, 
which has a similar impact to that of anti-angiogenic factors, as demonstrated by changes in 
p53 levels in hypoxia. It is important for these three reactions to remain in equilibrium 
during myocardial ischemia. Additionally, several factors can be both pro- and anti-
angiogenic in subsequent studies illustrating the intricacies innate to blood vessel growth. 
9. Clinical relevance to coronary artery diseases 
Current approaches available for patients with ischemic heart disease include medical 
therapy or coronary revascularization by percutaneous coronary angioplasty or coronary 
artery bypass grafting. Problems with these approaches include that many of the patients 
are not candidates for coronary revascularization procedures or achieve incomplete 
revascularization with these procedures. It is necessary to discover candidate molecules able 
to stimulate myocardial angiogenesis for therapeutic application. Preliminary clinical 
experiences suggest that therapeutic angiogenesis may provide additional blood flow to 
incompletely revascularized areas. Therapeutic angiogenesis with either HIF-1 or VEGF 
resulted in a marked increase in blood flow and improved cardiac function in animal 
studies without apparent toxicity (Simons, 2005). However, the results of clinical trials have 
been inconsistent and largely disappointing (Simons, 2005), presumably because the 
negative feedback of angiogenesis during hypoxia may explain the inadequate natural 
collateral circulation in hypoxic coronary diseases, in which upregulated VEGF inhibits 
other proangiogenic signaling or triggers angiogenic inhibitor signaling.  
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